Poland· PL-100013399

Cefobid

A cefoperazone product containing cefoperazonum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 2 of our 19 countries.

ATC J01DD12

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedCefobidATCJ01DD12REGISTER NO.PL-100013399PACKS LISTED1CHECKEDAugust 23, 2026

Where it is registered

Cefoperazone is registered in 2 of 19 countries.

Countries holding a registration under ATC J01DD12 (cefoperazone), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 2 of them publish a price we can compare per daily dose

Cefoperazone · ATC J01DD12

2 / 19 countries

  • Czechiaprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Cefoperazonum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
J01DD12
ATC class
Cefoperazone
Defined daily dose
4 g, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
August 23, 2026

Packs & prices · 1

  • gtin
    05909990065011

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

25 interactions on record for cefoperazone.

Graded by severity as the source publishes them — 25 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cefoperazone · interactions on record

25 records

  • 25 moderate

Most severe, free to view

  • Sodium picosulfateA06AB08moderate
  • NeomycinA07AA01moderate
  • StreptomycinA07AA04moderate
  • KanamycinA07AA08moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cefoperazone in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cefoperazone products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Bulgaria · Медоцеф
  • Cyprus · Medocef, Syntocef
  • Czechia · Acefa
  • Romania · Cefozon, Medocef

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/467da800-4879-48e9-adf7-bd18772b2090
GET /v1/drugs/467da800-4879-48e9-adf7-bd18772b2090?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do wstrzykiwań i infuzji",
  "source": "urpl",
  "strength": "1 g",
  "packaging": "05909990065011 ¦ Lz ¦ 2362\n1 fiol.",
  "substance": "Cefoperazonum 1 g",
  "common_name": "Cefoperazonum",
  "pl_product_id": "100013399",
  "pozwolenie_nr": "00650",
  "auth_procedure": "NAR",
  "authorisation_validity": "2023-08-24"
}

See everything about cefoperazone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.